End-of-day quote
Johannesburg S.E.
23:00:00 08/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.81
ZAR
|
0.00%
|
|
+1.25%
|
+3.85%
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,322
|
2,282
|
407.3
|
280.4
|
328.7
|
412.1
|
Enterprise Value (EV)
1 |
10,257
|
7,632
|
7,233
|
6,893
|
753.1
|
357
|
P/E ratio
|
18.2
x
|
-0.49
x
|
-0.4
x
|
-0.26
x
|
0.73
x
|
5.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.69
x
|
0.41
x
|
0.06
x
|
0.13
x
|
0.21
x
|
0.27
x
|
EV / Revenue
|
1.33
x
|
1.37
x
|
1.04
x
|
3.09
x
|
0.48
x
|
0.23
x
|
EV / EBITDA
|
8.19
x
|
54.4
x
|
7.45
x
|
-168
x
|
-35.2
x
|
-4.11
x
|
EV / FCF
|
-65.7
x
|
-2.25
x
|
-7.84
x
|
-1.48
x
|
0.13
x
|
-9.22
x
|
FCF Yield
|
-1.52%
|
-44.4%
|
-12.8%
|
-67.6%
|
766%
|
-10.8%
|
Price to Book
|
0.8
x
|
1.16
x
|
0.34
x
|
0.81
x
|
0.81
x
|
0.73
x
|
Nbr of stocks (in thousands)
|
488,298
|
485,499
|
484,827
|
483,494
|
483,452
|
624,379
|
Reference price
2 |
10.90
|
4.700
|
0.8400
|
0.5800
|
0.6800
|
0.6600
|
Announcement Date
|
21/09/18
|
31/10/19
|
30/09/20
|
30/09/21
|
27/09/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7,737
|
5,574
|
6,963
|
2,229
|
1,559
|
1,535
|
EBITDA
1 |
1,252
|
140.4
|
971.3
|
-41.04
|
-21.4
|
-86.9
|
EBIT
1 |
933.7
|
-80.41
|
589.9
|
-101.1
|
-67.38
|
-145.1
|
Operating Margin
|
12.07%
|
-1.44%
|
8.47%
|
-4.53%
|
-4.32%
|
-9.45%
|
Earnings before Tax (EBT)
1 |
564
|
-4,632
|
-959.1
|
-1,531
|
-795.4
|
-284.6
|
Net income
1 |
277.2
|
-4,670
|
-1,001
|
-1,091
|
449.2
|
75.32
|
Net margin
|
3.58%
|
-83.78%
|
-14.37%
|
-48.94%
|
28.8%
|
4.91%
|
EPS
2 |
0.5999
|
-9.633
|
-2.096
|
-2.265
|
0.9312
|
0.1242
|
Free Cash Flow
1 |
-156.2
|
-3,386
|
-922.3
|
-4,661
|
5,766
|
-38.71
|
FCF margin
|
-2.02%
|
-60.75%
|
-13.24%
|
-209.1%
|
369.73%
|
-2.52%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
1,283.57%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/09/18
|
31/10/19
|
30/09/20
|
30/09/21
|
27/09/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
4,934
|
5,350
|
6,826
|
6,613
|
424
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
55.1
|
Leverage (Debt/EBITDA)
|
3.942
x
|
38.11
x
|
7.027
x
|
-161.1
x
|
-19.83
x
|
-
|
Free Cash Flow
1 |
-156
|
-3,386
|
-922
|
-4,661
|
5,766
|
-38.7
|
ROE (net income / shareholders' equity)
|
8.2%
|
-107%
|
-54.7%
|
-167%
|
-166%
|
-59.3%
|
ROA (Net income/ Total Assets)
|
3.84%
|
-0.37%
|
3.13%
|
-0.55%
|
-0.68%
|
-6.85%
|
Assets
1 |
7,225
|
1,263,633
|
-31,932
|
197,538
|
-65,673
|
-1,100
|
Book Value Per Share
2 |
13.70
|
4.050
|
2.490
|
0.7200
|
0.8300
|
0.9000
|
Cash Flow per Share
2 |
1.580
|
0.6000
|
0.8200
|
0.7600
|
0.4400
|
0.1600
|
Capex
1 |
255
|
262
|
213
|
39.2
|
55.5
|
35.7
|
Capex / Sales
|
3.3%
|
4.71%
|
3.05%
|
1.76%
|
3.56%
|
2.33%
|
Announcement Date
|
21/09/18
|
31/10/19
|
30/09/20
|
30/09/21
|
27/09/22
|
29/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +3.85% | 27.5M | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|